RS67202B1 - Supstituisana makrociklična jedinjenja i srodni postupci lečenja - Google Patents
Supstituisana makrociklična jedinjenja i srodni postupci lečenjaInfo
- Publication number
- RS67202B1 RS67202B1 RS20250911A RSP20250911A RS67202B1 RS 67202 B1 RS67202 B1 RS 67202B1 RS 20250911 A RS20250911 A RS 20250911A RS P20250911 A RSP20250911 A RS P20250911A RS 67202 B1 RS67202 B1 RS 67202B1
- Authority
- RS
- Serbia
- Prior art keywords
- compound
- pharmaceutically acceptable
- mmol
- formula
- acceptable salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962939825P | 2019-11-25 | 2019-11-25 | |
| US202063030979P | 2020-05-28 | 2020-05-28 | |
| EP20828463.8A EP4065585B1 (en) | 2019-11-25 | 2020-11-25 | Substituted macrocyclic compounds and related methods of treatment |
| PCT/US2020/062320 WO2021108628A1 (en) | 2019-11-25 | 2020-11-25 | Substituted macrocyclic compounds and related methods of treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS67202B1 true RS67202B1 (sr) | 2025-10-31 |
Family
ID=73856348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20250911A RS67202B1 (sr) | 2019-11-25 | 2020-11-25 | Supstituisana makrociklična jedinjenja i srodni postupci lečenja |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US11542276B2 (https=) |
| EP (2) | EP4628167A3 (https=) |
| JP (2) | JP7787812B2 (https=) |
| KR (1) | KR20220106793A (https=) |
| CN (1) | CN114761412B (https=) |
| AU (2) | AU2020394444B2 (https=) |
| BR (1) | BR112022009938A2 (https=) |
| CA (1) | CA3155885A1 (https=) |
| DK (1) | DK4065585T3 (https=) |
| ES (1) | ES3041424T3 (https=) |
| FI (1) | FI4065585T3 (https=) |
| HR (1) | HRP20251156T1 (https=) |
| HU (1) | HUE073461T2 (https=) |
| IL (2) | IL293240B2 (https=) |
| LT (1) | LT4065585T (https=) |
| MA (1) | MA57908B1 (https=) |
| MD (1) | MD4065585T2 (https=) |
| MX (1) | MX2022006206A (https=) |
| PT (1) | PT4065585T (https=) |
| RS (1) | RS67202B1 (https=) |
| SA (1) | SA522432691B1 (https=) |
| SI (1) | SI4065585T1 (https=) |
| SM (1) | SMT202500340T1 (https=) |
| WO (1) | WO2021108628A1 (https=) |
| ZA (1) | ZA202206482B (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI4065585T3 (fi) | 2019-11-25 | 2025-09-26 | Alkermes Inc | Substituoituja makrosyklisiä yhdisteitä ja niihin liittyviä hoitomenetelmiä |
| US12503475B2 (en) | 2020-09-03 | 2025-12-23 | Centessa Pharmaceuticals (Uk) Limited | Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists |
| WO2022051583A1 (en) * | 2020-09-03 | 2022-03-10 | Orexia Therapeutics Limited | Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and their uses as orexin-2 receptor agonists |
| WO2022109117A1 (en) * | 2020-11-23 | 2022-05-27 | Merck Sharp & Dohme Corp. | 3-amino pyrrolidine and piperidine macrocyclic orexin receptor agonists |
| US12006330B2 (en) | 2020-12-21 | 2024-06-11 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| WO2022232025A1 (en) * | 2021-04-26 | 2022-11-03 | Alkermes, Inc. | Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity |
| EP4347046A1 (en) * | 2021-05-26 | 2024-04-10 | Alkermes, Inc. | Substituted fused bicyclic macrocyclic compounds and related methods of treatment |
| WO2022251304A1 (en) * | 2021-05-26 | 2022-12-01 | Alkerme, Inc. | Substituted carbamate macrocyclic compounds and related methods of treatment |
| KR20240157067A (ko) * | 2022-03-01 | 2024-10-31 | 센테사 파마슈티칼스 (유케이) 리미티드 | 미디엄- 또는 마크로-시클릭 벤질-치환된 헤테로사이클 유도체 및 관련 용도 |
| WO2024095158A1 (en) * | 2022-10-31 | 2024-05-10 | Takeda Pharmaceutical Company Limited | Dosing of orexin type 2 receptor agonists |
| EP4622712A1 (en) * | 2022-11-23 | 2025-10-01 | Vertex Pharmaceuticals Incorporated | Substituted macrocyclic amine modulators of orexin receptor 2 |
| TW202430169A (zh) | 2022-12-16 | 2024-08-01 | 日商第一三共股份有限公司 | 2-氮雜雙環[3.1.1]庚烷化合物 |
| EP4658660A1 (en) | 2023-01-31 | 2025-12-10 | Jazz Pharmaceuticals Ireland Limited | Macrocyclic orexin receptor agonists and uses thereof |
| KR20250155550A (ko) | 2023-03-16 | 2025-10-30 | 다케다 야쿠힌 고교 가부시키가이샤 | 매크로시클릭 헤테로시클 화합물 및 이의 용도 |
| US20240425521A1 (en) * | 2023-06-01 | 2024-12-26 | H. Lundbeck A/S | Spiromacrocyclic orexin 2 receptor agonists |
| TW202502342A (zh) | 2023-06-02 | 2025-01-16 | 日商武田藥品工業股份有限公司 | 食慾素２受體促效劑用於改善睡眠期間之呼吸功能的用途 |
| AU2024361979A1 (en) * | 2023-10-20 | 2026-03-05 | Alkermes, Inc. | Compound for use in treating narcolepsy |
| WO2025096445A1 (en) | 2023-10-30 | 2025-05-08 | Alkermes, Inc. | Synthesis of intermediates for the preparation of macrocyclic compounds |
| WO2025124698A1 (en) | 2023-12-12 | 2025-06-19 | Idorsia Pharmaceuticals Ltd | Aryl sulfone and sulfanone derivatives as orexin receptor modulators |
| TW202542165A (zh) | 2023-12-19 | 2025-11-01 | 瑞士商愛杜西亞製藥有限公司 | 大環食慾素激動劑 |
| TW202547576A (zh) * | 2024-04-04 | 2025-12-16 | 日商橘生藥品工業股份有限公司 | 取代磺醯胺巨環狀化合物 |
| WO2025224168A1 (en) | 2024-04-24 | 2025-10-30 | Idorsia Pharmaceuticals Ltd | Aryl sulfone and sulfanone derivatives as orexin receptor modulators |
| WO2025229493A1 (en) | 2024-04-29 | 2025-11-06 | Takeda Pharmaceutical Company Limited | Dosing of orexin type 2 receptor agonists |
| WO2026017128A1 (zh) * | 2024-07-17 | 2026-01-22 | 江苏恩华药业股份有限公司 | 作为食欲素受体激动剂的环烯烃衍生物及其组合物和用途 |
Family Cites Families (113)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0939121B2 (de) | 1989-09-12 | 2007-12-26 | AHP Manufacturing B.V. | TFN-bindende Proteine |
| US5635599A (en) | 1994-04-08 | 1997-06-03 | The United States Of America As Represented By The Department Of Health And Human Services | Fusion proteins comprising circularly permuted ligands |
| EP1027373B1 (en) | 1997-10-31 | 2006-09-06 | Biomira, Inc. | Muc-1 derivatives and their use in treating cancer-associated muc-1 mucin-induced immunosuppression |
| WO1999046392A1 (en) | 1998-03-12 | 1999-09-16 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines |
| EP1066322A1 (en) | 1998-04-03 | 2001-01-10 | The University of Washington | Circularly permuted biotin binding proteins |
| WO2000029447A1 (en) | 1998-11-19 | 2000-05-25 | Smithkline Beecham Corporation | Rhamm antagonist antibodies |
| US6428985B1 (en) | 1998-12-02 | 2002-08-06 | The Regents Of The University Of Michigan | Immunosuppressive structural definition of IL-10 |
| US7754855B1 (en) | 1999-07-13 | 2010-07-13 | Bolder Biotechnology, Inc. | Immunoglobulin fusion proteins |
| US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
| CA2391080A1 (en) | 1999-11-12 | 2001-05-25 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Erythropoietin forms with improved properties |
| WO2001058950A1 (en) | 2000-02-11 | 2001-08-16 | Maxygen Aps | Improved interleukin 10 |
| EP1272467A4 (en) | 2000-04-06 | 2003-05-07 | Merck Frosst Canada Inc | Cathepsin cysteine protease inhibitors |
| IL155812A0 (en) | 2000-12-07 | 2003-12-23 | Lilly Co Eli | Glp-1 fusion proteins |
| JP2004519230A (ja) | 2001-02-06 | 2004-07-02 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 低減された免疫原性を有する修飾されたインターロイキン−１受容体アンタゴニスト（ｉｌ−１ｒａ） |
| CA2454469A1 (en) | 2001-07-20 | 2003-02-06 | Absorber, Ab | Blood group antigen fusion polypeptides and methods of use thereof |
| US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| EP1534748A2 (en) | 2002-08-09 | 2005-06-01 | Recopharma AB | Fusion proteins and methods of producing same |
| AU2003280315A1 (en) | 2002-11-14 | 2004-06-03 | Maxygen, Inc. | Conjugates of interleukin-10 and polymers |
| WO2004060911A2 (en) | 2002-12-30 | 2004-07-22 | Amgen Inc. | Combination therapy with co-stimulatory factors |
| PL2298347T3 (pl) | 2003-05-06 | 2016-03-31 | Bioverativ Therapeutics Inc | Białka chimeryczne czynnika krzepnięcia do leczenia zaburzenia hemostazy |
| US7696322B2 (en) | 2003-07-28 | 2010-04-13 | Catalent Pharma Solutions, Inc. | Fusion antibodies |
| US20150071948A1 (en) | 2003-09-26 | 2015-03-12 | Gregory Alan Lazar | Novel immunoglobulin variants |
| WO2005034863A2 (en) | 2003-10-03 | 2005-04-21 | Jarikuma Corporation | Countermeasures against malaria |
| WO2005042573A1 (en) | 2003-10-24 | 2005-05-12 | Dana-Farber Cancer Institute, Inc. | Modulation of the interaction of muc1 with muc1 ligands |
| US8454963B2 (en) | 2003-11-13 | 2013-06-04 | Musc Foundation For Research Development | Tissue targeted complement modulators |
| US7576183B2 (en) | 2003-12-24 | 2009-08-18 | Los Alamos National Security, Llc | Structure-based receptor MIMICS targeted against bacterial superantigen toxins |
| CA2583983C (en) | 2004-10-14 | 2013-07-16 | Abbott Gmbh & Co. Kg | Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| MX2007006214A (es) | 2004-11-24 | 2008-04-16 | Therakine Ltd | Un implante para suministro de farmaco intraocular. |
| CN101163477A (zh) | 2005-02-23 | 2008-04-16 | 普雷萨药品公司 | 多介质多巴胺转运抑制剂，以及其相关应用 |
| CA2618791C (en) | 2005-08-12 | 2014-05-13 | Riken | Novel mucin-type glycoprotein and use thereof |
| US20100016547A1 (en) | 2005-11-30 | 2010-01-21 | Takaomi Ito | Glycosilated Peptide and Medicine Comprising It as an Effective Ingredient |
| DE602005015733D1 (de) | 2005-12-02 | 2009-09-10 | Apceth Gmbh & Co Kg | Chemokin-Mucin Fusionsproteine mit einer GPI-Ankerdomäne und deren Verwendung als Tumor-Immun-Adjuvanzien oder in der Geweberegeneration |
| WO2008140595A2 (en) | 2006-12-01 | 2008-11-20 | President And Fellows Of Harvard College | Synthetic trivalent haptens, complexes thereof, and uses therefor |
| WO2008133928A2 (en) | 2007-04-27 | 2008-11-06 | The Gi Company, Inc. | Mucin glycoproteins and their use for treatment of epithelial lesions and mucin dependent disorders |
| JP2010536341A (ja) | 2007-08-15 | 2010-12-02 | アムニクス， インコーポレイテッド | 生物学的に活性なポリペプチドの特性を改変するための組成物および方法 |
| US8258163B2 (en) | 2008-06-04 | 2012-09-04 | Board Of Regents, The University Of Texas System | Small-molecule agonists for type-2 orexin receptor |
| US8765669B2 (en) | 2008-06-17 | 2014-07-01 | Glytech, Inc. | Glycosylated GLP-1 peptide |
| ES2411916T3 (es) | 2008-08-14 | 2013-07-09 | Janssen R&D Ireland | Derivados indólicos macrocíclicos útiles como inhibidores del virus de la hepatitis c |
| EP3028707A1 (en) | 2009-05-01 | 2016-06-08 | Ophthotech Corporation | Methods for treating or preventing ophthalmological diseases |
| BRPI1014583B1 (pt) | 2009-06-26 | 2020-03-31 | Pfizer, Inc. | Sulfonamidas heterocíclicas e composições farmacêuticas |
| BR112012017164A2 (pt) | 2009-12-22 | 2019-09-24 | Novartis Ag | proteína de fusão de região constante de anticorpo-cd47 tetravalente |
| CA2785907A1 (en) | 2009-12-29 | 2011-07-28 | Emergent Product Development Seattle, Llc | Ron binding constructs and methods of use thereof |
| AR080993A1 (es) | 2010-04-02 | 2012-05-30 | Hanmi Holdings Co Ltd | Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina |
| CN101962413B (zh) | 2010-09-21 | 2013-03-13 | 中国科学技术大学 | 具有透皮能力和白细胞介素-10活性的融合蛋白及其编码基因与应用 |
| US8883134B2 (en) | 2010-10-20 | 2014-11-11 | Handok Pharmaceuticals, Inc. | Human interleukin-1 receptor antagonist—hybrid Fc fusion protein |
| EP2457579A1 (en) | 2010-11-26 | 2012-05-30 | Technische Universität Dresden | Covalently linked interleukin -10 |
| TWI743461B (zh) | 2011-03-28 | 2021-10-21 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| EP2694472B1 (en) | 2011-04-05 | 2020-03-11 | Takeda Pharmaceutical Company Limited | Sulfonamide derivative and use thereof |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| EP2723380B1 (en) | 2011-06-24 | 2019-08-21 | Stephen D. Gillies | Light chain immunoglobulin fusion proteins and methods of use thereof |
| NO2748201T3 (https=) | 2011-08-23 | 2018-05-12 | ||
| US10017481B2 (en) | 2012-03-17 | 2018-07-10 | Polyphor Ag | Conformationally constrained, fully synthetic macrocyclic compounds |
| US9062120B2 (en) | 2012-05-02 | 2015-06-23 | Janssen Biotech, Inc. | Binding proteins having tethered light chains |
| EP2851429B1 (en) | 2012-05-18 | 2019-07-24 | Adda Biotech Inc. | Protein and protein conjugate for diabetes treatment, and applications thereof |
| US9156897B2 (en) | 2012-06-08 | 2015-10-13 | Alkermes, Inc. | Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide |
| IN2015DN01299A (https=) | 2012-07-23 | 2015-07-03 | Zymeworks Inc | |
| PE20150645A1 (es) | 2012-08-08 | 2015-05-11 | Roche Glycart Ag | Proteinas de fusion de interleuquina 10 y usos de las mismas |
| US11634502B2 (en) | 2013-03-15 | 2023-04-25 | Amgen Inc. | Heterodimeric bispecific antibodies |
| EP2989240A4 (en) | 2013-04-24 | 2016-10-19 | Armo Biosciences Inc | INTERLEUKIN-10 COMPOSITIONS AND USES THEREOF |
| WO2014198880A1 (en) | 2013-06-14 | 2014-12-18 | Ferrer Internacional, S.A. | 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity |
| CA2919076C (en) | 2013-07-31 | 2024-01-30 | Amgen Inc. | Stabilization of fc-containing polypeptides |
| US20160250224A1 (en) | 2013-09-24 | 2016-09-01 | The Board Of Regents Of The University Of Texas System | Orexin-control of bone formation and loss |
| CA2930693A1 (en) | 2013-11-15 | 2015-05-21 | The Board Of Trustees Of The Leland Stanford Junior Unversity | Methods of treating heart failure with agonists of hypocretin receptor 2 |
| PE20161064A1 (es) | 2013-12-12 | 2016-10-28 | Univ Tsukuba | Derivado de sulfonamida o sales de adicion de acido farmaceuticamente aceptables del mismo |
| WO2015117930A1 (en) | 2014-02-06 | 2015-08-13 | F. Hoffmann-La Roche Ag | Interleukine 10 immunoconjugates |
| WO2015147240A1 (ja) | 2014-03-28 | 2015-10-01 | 国立大学法人筑波大学 | 敗血症の予防治療剤 |
| KR102455043B1 (ko) | 2014-09-11 | 2022-10-13 | 얀센 파마슈티카 엔.브이. | 치환된 2-아자바이사이클 및 오렉신 수용체 조절제로서의 이의 용도 |
| CN104403004B (zh) | 2014-11-24 | 2017-10-13 | 苏州丁孚靶点生物技术有限公司 | 抗体‑干扰素异二聚体的制备和用途 |
| AU2015364396B2 (en) | 2014-12-19 | 2018-08-09 | Alkermes, Inc. | Single chain Fc fusion proteins |
| WO2016101119A1 (en) * | 2014-12-23 | 2016-06-30 | Merck Sharp & Dohme Corp. | Fused heteroaryl derivatives as orexin receptor antagonists |
| WO2016133160A1 (ja) | 2015-02-19 | 2016-08-25 | 国立大学法人筑波大学 | スルホンアミド誘導体またはその薬学的に許容される酸付加塩 |
| WO2016199906A1 (ja) | 2015-06-12 | 2016-12-15 | 国立大学法人筑波大学 | スルホンアミド誘導体またはその薬学的に許容される酸付加塩 |
| CN107787322B (zh) * | 2015-06-17 | 2023-07-07 | 辉瑞大药厂 | 三环化合物以及它们作为磷酸二酯酶抑制剂的用途 |
| BR112018003588A2 (pt) * | 2015-08-26 | 2018-09-25 | Blueprint Medicines Corp | compostos e composições úteis para tratamento de distúrbios relacionados ao ntrk |
| CN108699065B (zh) * | 2015-12-18 | 2021-08-31 | 诺华股份有限公司 | 作为激酶抑制剂的三环类化合物和组合物 |
| PL3411358T3 (pl) | 2016-02-04 | 2022-02-28 | Takeda Pharmaceutical Company Limited | Podstawiony związek piperydynowy i jego zastosowanie |
| WO2017165464A1 (en) | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| WO2018005226A2 (en) | 2016-06-22 | 2018-01-04 | Alkermes, Inc. | Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties |
| WO2018164191A1 (ja) | 2017-03-08 | 2018-09-13 | 武田薬品工業株式会社 | 置換ピロリジン化合物およびその用途 |
| US11034700B2 (en) | 2017-03-08 | 2021-06-15 | Takeda Pharmaceutical Company Limited | Substituted pyrrolidine compound and use thereof |
| US20200207734A1 (en) | 2017-08-03 | 2020-07-02 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| US11319286B2 (en) | 2017-08-03 | 2022-05-03 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
| CN111132975B (zh) | 2017-09-28 | 2023-05-23 | 勃林格殷格翰国际有限公司 | N-(2,2-二氟乙基)-n-[(嘧啶基氨基)丙基]芳基甲酰胺 |
| WO2019117148A1 (ja) | 2017-12-12 | 2019-06-20 | 国立大学法人 筑波大学 | スルホンアミド誘導体またはその薬学的に許容される酸付加塩 |
| MX2020010155A (es) | 2018-03-27 | 2021-03-25 | Univ Texas | Compuestos de ox2r. |
| US12077522B2 (en) | 2018-06-29 | 2024-09-03 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
| JP7413261B2 (ja) | 2018-06-29 | 2024-01-15 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| EP3896060B1 (en) | 2018-12-12 | 2023-08-16 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| JP7379374B2 (ja) | 2018-12-12 | 2023-11-14 | 武田薬品工業株式会社 | 複素環化合物 |
| SG11202106791XA (en) | 2019-01-31 | 2021-07-29 | Takeda Pharmaceuticals Co | Heterocyclic compound and use thereof |
| WO2020167701A1 (en) | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | Pyrrolidine orexin receptor agonists |
| US11098029B2 (en) | 2019-02-13 | 2021-08-24 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
| WO2021026047A1 (en) | 2019-08-08 | 2021-02-11 | Merck Sharp & Dohme Corp. | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
| BR112022004576A2 (pt) | 2019-09-13 | 2022-06-14 | Takeda Pharmaceuticals Co | Métodos para diminuir ou tratar sonolência excessiva, tratar narcolepsia tipo 2 ou hipersonia idiopática, tratar distúrbio de trabalho de turno, aumentar latência de sono em manutenção de teste de insônia, melhorar classificação de escaça de sonolência de karolinska, diminuir ou melhorar sonolência subjetiva, aumentar insônia ou diminuir sonolência excessiva, melhorar classificação de escala de sonolência epworth, tratar narcolepsia tipo 2, diminuir ou tratar sonolência diurna excessiva, e, composição farmacêutica |
| FI4065585T3 (fi) | 2019-11-25 | 2025-09-26 | Alkermes Inc | Substituoituja makrosyklisiä yhdisteitä ja niihin liittyviä hoitomenetelmiä |
| US11352357B2 (en) | 2019-11-27 | 2022-06-07 | Sumitomo Dainippon Pharma Co., Ltd. | Cycloalkylurea derivative |
| WO2021106975A1 (ja) | 2019-11-27 | 2021-06-03 | 武田薬品工業株式会社 | 複素環化合物 |
| MX2022008392A (es) | 2020-01-10 | 2022-08-08 | Takeda Pharmaceuticals Co | Metodo para mejorar la farmacocinetica o aumentar la concentracion de plasma de 3-((metilsulfonil)amino)-2-(((4-fenilci clohexil)oxi)metil)piperidina-1-carboxilato de metilo o una sal del mismo con un inhibidor de citocromo p450. |
| KR20230040953A (ko) | 2020-07-17 | 2023-03-23 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 치환된 피페리딘 화합물 및 이의 적용례 |
| BR112023002957A2 (pt) | 2020-08-18 | 2023-04-04 | Merck Sharp & Dohme Llc | Composto, composição farmacêutica, e, métodos para tratar narcolepsia e para tratar hipersonia em um sujeito mamífero |
| EP4199925A4 (en) | 2020-08-18 | 2024-08-28 | Merck Sharp & Dohme LLC | CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTS |
| US12503475B2 (en) | 2020-09-03 | 2025-12-23 | Centessa Pharmaceuticals (Uk) Limited | Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists |
| WO2022051583A1 (en) | 2020-09-03 | 2022-03-10 | Orexia Therapeutics Limited | Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and their uses as orexin-2 receptor agonists |
| JP2022064180A (ja) | 2020-10-13 | 2022-04-25 | 武田薬品工業株式会社 | 複素環化合物 |
| EP4236938A4 (en) | 2020-11-02 | 2024-10-16 | Merck Sharp & Dohme LLC | MACROCYCLIC UREA-OREX RECEPTOR AGONISTS |
| WO2022109117A1 (en) | 2020-11-23 | 2022-05-27 | Merck Sharp & Dohme Corp. | 3-amino pyrrolidine and piperidine macrocyclic orexin receptor agonists |
| EP4255429A4 (en) | 2020-12-03 | 2024-12-11 | Merck Sharp & Dohme LLC | 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists |
| US20240101555A1 (en) | 2020-12-16 | 2024-03-28 | Merck Sharp & Dohme Llc | Urea orexin receptor agonists |
| US12006330B2 (en) | 2020-12-21 | 2024-06-11 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| US20240174605A1 (en) | 2021-03-03 | 2024-05-30 | Research Triangle Institute | Arylsulfonamides as orexin receptor agonists |
| WO2022207935A1 (en) | 2021-04-02 | 2022-10-06 | Orexia Therapeutics Limited | 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists |
| KR20240004802A (ko) | 2021-05-03 | 2024-01-11 | 재즈 파마슈티칼즈 아일랜드 리미티드 | 오렉신 수용체 효능제 및 그의 용도 |
-
2020
- 2020-11-25 FI FIEP20828463.8T patent/FI4065585T3/fi active
- 2020-11-25 EP EP25195771.8A patent/EP4628167A3/en active Pending
- 2020-11-25 BR BR112022009938A patent/BR112022009938A2/pt unknown
- 2020-11-25 EP EP20828463.8A patent/EP4065585B1/en active Active
- 2020-11-25 JP JP2022529454A patent/JP7787812B2/ja active Active
- 2020-11-25 US US17/104,993 patent/US11542276B2/en active Active
- 2020-11-25 PT PT208284638T patent/PT4065585T/pt unknown
- 2020-11-25 WO PCT/US2020/062320 patent/WO2021108628A1/en not_active Ceased
- 2020-11-25 RS RS20250911A patent/RS67202B1/sr unknown
- 2020-11-25 SM SM20250340T patent/SMT202500340T1/it unknown
- 2020-11-25 CN CN202080081320.8A patent/CN114761412B/zh active Active
- 2020-11-25 AU AU2020394444A patent/AU2020394444B2/en active Active
- 2020-11-25 MA MA57908A patent/MA57908B1/fr unknown
- 2020-11-25 ES ES20828463T patent/ES3041424T3/es active Active
- 2020-11-25 IL IL293240A patent/IL293240B2/en unknown
- 2020-11-25 IL IL320038A patent/IL320038A/en unknown
- 2020-11-25 MX MX2022006206A patent/MX2022006206A/es unknown
- 2020-11-25 HU HUE20828463A patent/HUE073461T2/hu unknown
- 2020-11-25 KR KR1020227021501A patent/KR20220106793A/ko active Pending
- 2020-11-25 LT LTEPPCT/US2020/062320T patent/LT4065585T/lt unknown
- 2020-11-25 DK DK20828463.8T patent/DK4065585T3/da active
- 2020-11-25 CA CA3155885A patent/CA3155885A1/en active Pending
- 2020-11-25 HR HRP20251156TT patent/HRP20251156T1/hr unknown
- 2020-11-25 MD MDE20221089T patent/MD4065585T2/ro unknown
- 2020-11-25 SI SI202030661T patent/SI4065585T1/sl unknown
-
2022
- 2022-05-23 SA SA522432691A patent/SA522432691B1/ar unknown
- 2022-06-10 ZA ZA2022/06482A patent/ZA202206482B/en unknown
- 2022-11-22 US US17/991,899 patent/US12054495B2/en active Active
-
2024
- 2024-06-17 US US18/745,031 patent/US20250092063A1/en active Pending
-
2025
- 2025-05-07 AU AU2025203295A patent/AU2025203295A1/en active Pending
- 2025-08-27 JP JP2025141156A patent/JP2025186272A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS67202B1 (sr) | Supstituisana makrociklična jedinjenja i srodni postupci lečenja | |
| US12006330B2 (en) | Substituted macrocyclic compounds and related methods of treatment | |
| JP7846113B2 (ja) | 置換ピペリジノ化合物及び関連する治療方法 | |
| EP4329877B1 (en) | Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity | |
| US20250223260A1 (en) | Substituted Pyrrolidinyl And Piperidinyl Compounds And Related Methods Of Treatment | |
| US20250223276A1 (en) | Substituted Pyrrolidinyl And Piperidinyl Compounds And Related Methods Of Treatment | |
| EP4543446A1 (en) | Substituted fused bicyclic compounds and related methods of treatment | |
| HK40129946A (en) | Substituted macrocyclic compounds and related methods of treatment | |
| HK40079289A (en) | Substituted macrocyclic compounds and related methods of treatment | |
| HK40079289B (en) | Substituted macrocyclic compounds and related methods of treatment | |
| EA047646B1 (ru) | Замещенные макроциклические соединения и связанные с ними способы лечения | |
| EA049565B1 (ru) | Замещенные макроциклические соединения, обладающие активностью агониста рецептора орексина-2, и их применение |